ARCA biopharma Statistics
Total Valuation
ARCA biopharma has a market cap or net worth of $52.06 million. The enterprise value is $15.99 million.
| Market Cap | 52.06M |
| Enterprise Value | 15.99M |
Important Dates
The last earnings date was Thursday, April 25, 2024, after market close.
| Earnings Date | Apr 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ARCA biopharma has 14.50 million shares outstanding. The number of shares has increased by 0.63% in one year.
| Shares Outstanding | 14.50M |
| Shares Change (YoY) | +0.63% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 1.29% |
| Owned by Institutions (%) | 71.80% |
| Float | 5.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.48 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.19, with zero debt.
| Current Ratio | 23.19 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.10% and return on invested capital (ROIC) is -22.72%.
| Return on Equity (ROE) | -16.10% |
| Return on Assets (ROA) | -15.50% |
| Return on Capital (ROIC) | -22.72% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.50M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +77.55% in the last 52 weeks. The beta is 1.21, so ARCA biopharma's price volatility has been higher than the market average.
| Beta (1Y) | 1.21 |
| 52-Week Price Change | +77.55% |
| 50-Day Moving Average | 2.23 |
| 200-Day Moving Average | 1.97 |
| Relative Strength Index (RSI) | 73.27 |
| Average Volume (30 Days) | 1,444,029 |
Short Selling Information
The latest short interest is 5.66 million, so 39.05% of the outstanding shares have been sold short.
| Short Interest | 5.66M |
| Short Previous Month | 195,728 |
| Short % of Shares Out | 39.05% |
| Short % of Float | 99.77% |
| Short Ratio (days to cover) | 7.31 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.98M |
| Pretax Income | -6.00M |
| Net Income | -6.00M |
| EBITDA | -5.90M |
| EBIT | -6.00M |
| Earnings Per Share (EPS) | -$0.42 |
Balance Sheet
The company has $35.90 million in cash and no debt, giving a net cash position of $35.90 million or $2.48 per share.
| Cash & Cash Equivalents | 35.90M |
| Total Debt | n/a |
| Net Cash | 35.90M |
| Net Cash Per Share | $2.48 |
| Equity / Book Value | 35.13M |
| Book Value Per Share | 2.42 |
| Working Capital | 35.09M |
Cash Flow
| Operating Cash Flow | -4.95M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.95M |
| FCF Per Share | -$0.34 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ARCA biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.63% |
| Shareholder Yield | -0.63% |
| Earnings Yield | -11.57% |
| FCF Yield | -9.53% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 4, 2019. It was a reverse split with a ratio of 1:18.
| Last Split Date | Apr 4, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |